Cerevance is a brand that is focused on developing treatments for central nervous system (CNS) disorders, with a specific emphasis on neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). Leveraging their extensive collection of over 14,000 human brain tissue samples, Cerevance is generating an unprecedented catalog of promising targets for next-generation treatments. They are utilizing their proprietary NETSseq platform and advanced machine learning techniques to identify previously undiscovered gene expression profiles in select cell types.

This approach allows them to find groundbreaking therapeutic approaches for patients. Cerevance boasts a team of world-leading scientists and drug developers who are dedicated to transforming the lives of patients affected by CNS disorders. With their cutting-edge technology and expertise, Cerevance is at the forefront of neuroscientific research and committed to bringing about innovative solutions for the treatment of neurological conditions